ESR1 and p53 Interactome Defines Mechanisms of Therapeutic Response to Tamoxifen Therapy in Luminal Breast Cancer Patients
RNA-seq (gene expression) · human · 35 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 35 samples: 35 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- ESR1 and p53 interactome alteration defines mechanisms of tamoxifen response in luminal breast canceriScience · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE263089_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1095632 and SRA study SRP499418. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 35 sample titles: 35 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8185657 03TR
- GSM8185658 05TR
- GSM8185659 06TR
- GSM8185660 07TR
- GSM8185661 08TR
- GSM8185662 09TR
- GSM8185663 10TR
- GSM8185664 13TR
- GSM8185665 15TR
- GSM8185666 16TR
- GSM8185667 18TR
- GSM8185668 21TR
- GSM8185669 22TR
- GSM8185670 23TR
- GSM8185671 24TR
- GSM8185672 29TR
- GSM8185673 30TR
- GSM8185674 32TR
- GSM8185675 33TR
- GSM8185676 35TR
- GSM8185677 36TR
- GSM8185678 39TR
- GSM8185679 14TR
- GSM8185680 19TR
- GSM8185681 20TR
- GSM8185682 25TR
- GSM8185683 26TR
- GSM8185684 27TR
- GSM8185685 31TR
- GSM8185686 34TR
- GSM8185687 37TR
- GSM8185688 38TR
- GSM8185689 41TR
- GSM8185690 28TR
- GSM8185691 40TR
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing · shares breast
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares breast
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing · shares breast
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing · shares breast
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE282082 Circular RNA circTNK2 contributes to immune evasion and acts as a nanotherapeutic target in tamoxifen-resistant ER-positive breast cancer 10 samples shares therapeutic, tamoxifen, breast
- GSE310672 Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation [RNA-seq] 48 samples shares esr1, breast
- GSE266407 ESR1 fusions invoke breast cancer subtype-dependent enrichment of ligand independent oncogenic signatures and phenotypes [ChIP-seq] 14 samples shares esr1, breast
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.